Literature DB >> 10383647

Accumulation of murine amyloidbeta42 in a gene-dosage-dependent manner in PS1 'knock-in' mice.

Y Nakano1, G Kondoh, T Kudo, K Imaizumi, M Kato, J I Miyazaki, M Tohyama, J Takeda, M Takeda.   

Abstract

The establishment of an animal model with a missense mutation of presenilin-1 (PS1) is an initial step toward understanding the molecular pathogenesis of familial Alzheimer's disease (FAD) and developing therapeutic strategies for the disease. We previously described a Japanese family with FAD caused by the I213T mutation of PS1, in which typical signs and symptoms of Alzheimer's disease were observed at the age of 45 +/- 4.2 years [Hardy, J. (1997) Trends. Neurosci., 20, 154-159; Kamino, K et al. (1996) Neurosci. Lett., 208, 195-198]. Here, we report the establishment of 'knock-in' mice with the I213T PS1 missense mutation. Northern blot and reverse transcription polymerase chain reaction (RT-PCR) analyses showed that the mutated PS1 allele was expressed at the same level as the endogenous PS1 allele, demonstrating that the PS1 missense mutation was successfully introduced into the mouse PS1 locus, and therefore that the situation mimics that in FAD patients bearing PS1 missense mutations. Amyloid beta (Abeta) 42(43) peptide, but not Abeta40 peptide, accumulated in 'knock-in' mice at the age of 16-20 weeks. A clear gene-dosage effect on the increase of Abeta42(43) was observed in 'knock-in' mice: the percentage increase of Abeta42(43) in mice with mutations in both alleles was twice as high as that in mice with a single allele. These results indicate that the level of the mutated PS1 gene expression is likely to be critically involved in the production of highly amyloidogenic Abeta42(43), and confirm that PS1 mutation has an important effect on amyloid precursor protein (APP) processing, in proportion to the level of the expression of the mutant gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10383647     DOI: 10.1046/j.1460-9568.1999.00698.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  23 in total

Review 1.  Metabolism of presenilins.

Authors:  G Thinakaran
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

Review 2.  Mouse models of Alzheimer's disease.

Authors:  Alicia M Hall; Erik D Roberson
Journal:  Brain Res Bull       Date:  2011-11-28       Impact factor: 4.077

3.  Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model.

Authors:  Caty Casas; Nicolas Sergeant; Jean-Michel Itier; Véronique Blanchard; Oliver Wirths; Nicolien van der Kolk; Valérie Vingtdeux; Evita van de Steeg; Gwenaëlle Ret; Thierry Canton; Hervé Drobecq; Allan Clark; Bruno Bonici; André Delacourte; Jesús Benavides; Christoph Schmitz; Günter Tremp; Thomas A Bayer; Patrick Benoit; Laurent Pradier
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

Review 4.  The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases.

Authors:  Konstanze F Winklhofer; Jörg Tatzelt; Christian Haass
Journal:  EMBO J       Date:  2008-01-23       Impact factor: 11.598

5.  Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability.

Authors:  R Siman; A G Reaume; M J Savage; S Trusko; Y G Lin; R W Scott; D G Flood
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

Review 6.  Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer's disease.

Authors:  J T Huse; R W Doms
Journal:  Mol Neurobiol       Date:  2000 Aug-Dec       Impact factor: 5.590

7.  Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo.

Authors:  Bonnie C Miller; Elizabeth A Eckman; Kumar Sambamurti; Nicole Dobbs; K Martin Chow; Christopher B Eckman; Louis B Hersh; Dwain L Thiele
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

8.  Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer's disease related biomarkers.

Authors:  Lina Adwan; Gehad M Subaiea; Nasser H Zawia
Journal:  Neuropharmacology       Date:  2014-01-21       Impact factor: 5.250

9.  Modeling presenilin-dependent familial Alzheimer's disease: emphasis on presenilin substrate-mediated signaling and synaptic function.

Authors:  Angèle T Parent; Gopal Thinakaran
Journal:  Int J Alzheimers Dis       Date:  2010-07-20

10.  PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations.

Authors:  Lia Baki; Junichi Shioi; Paul Wen; Zhiping Shao; Alexander Schwarzman; Miguel Gama-Sosa; Rachael Neve; Nikolaos K Robakis
Journal:  EMBO J       Date:  2004-06-10       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.